"Etude rétrospective des cas de vasculite cutanée identifiés au laboratoire de dermopathologie du CHUV de 2006 à 2010"

CONTEXTE Les vasculites représentent un groupe de maladies inflammatoires touchant tous les vaisseaux, des grosses artères aux artères de plus petit calibre, en passant par les capillaires et les veines, de toutes tailles également. La taille des vaisseaux atteints est d'une importance cruciale pour le diagnostic puisque la classification actuelle en dépend. Sur le plan histopathologique, la vasculite est une réaction inflammatoire qui atteint la paroi de vaisseaux, et qui va entraîner alors une ischémie, puis une nécrose du vaisseau lui-­‐ même voire des structures environnantes ; les caractéristiques microscopiques de ces lésions permettent souvent d'aider à préciser le groupe auquel appartient la vasculite. Cependant, il n'est pas toujours facile ni possible d'obtenir un échantillon de tissu, une biopsie, selon l'endroit concerné (cerveau, régions profondes et difficilement accessibles...). OBJECTIFS Dans les atteintes de type « vasculite », la peau est fréquemment un organe cible. Le grand avantage est son accès direct et aisé, notamment dans le but de pratiquer un examen histopathologique par le biais d'une biopsie, qui peut se pratiquer de manière superficielle ou profonde, révélant alors des vaisseaux de différents calibres. Face à un tableau clinique parfois complexe et menaçant, il est important de pouvoir orienter le diagnostic rapidement. L'objectif de ce travail est donc de déterminer quelles sont l'utilité et l'apport de la biopsie cutanée dans le diagnostic des vasculites, et autrement dit de déterminer s'il vaut la peine de pratiquer ce genre d'examen, ou s'il vaut mieux privilégier d'autres approches plus rentables sur ce plan-­‐là. METHODES Grâce à l'aide des dermatologues et à la base de données du Service de dermatopathologie du CHUV, nous nous proposons de faire une étude rétrospective et systématique, sur les 5 années passées, de toutes les biopsies cutanées compatibles avec le diagnostic de vasculite. RESULTATS ESCOMPTES Ils sont de deux ordres : déterminer d'une part si le résultat de la biopsie était compatible avec le diagnostic clinique retenu chez les patients ayant subi ce type d'examen. Cela nous permettra alors d'établir des recommandations pour la réalisation éventuelle d'une biopsie cutanée dans ce type de situation. Il sera en effet capital de savoir si ce geste est utile et, le cas échéant, s'il faut demander une biopsie profonde ou si une biopsie superficielle est suffisante. Ce travail nous permettra d'autre part de revoir les caractéristiques cutanées -­‐ sur le plan histopathologique -­‐ des vasculites, et de déterminer aussi leur fréquence. Dans l'idéal, ce travail devrait permettre de faire la revue et la mise à jour des connaissances dans le domaine des vasculites cutanées, utiles aux praticiens notamment.

Prévention des maladies et promotion de la santé: propositions pour une stratégie vaudoise : stratégie dans quelques régions : complément au rapport de mars 2007

[Table des matières] Introduction. 2 Stratégies de prévention dans d'autres régions. 3. Australie (Australian Better Health Initiative 2006-2010). 4. Royaume-Uni. 5. Suisse. 5.1 En résumé ... 5.2 Vers une loi fédérale (?) 5.3 Suisse : synopsis. 6. Saint-Gall. 6.1 Poids corporel sain pour les enfants. 6.2 Santé au travail. 6.3 Dépendances. 6.4 Prévention et promotion de la santé dans les communes. 6.5 Saint-Gall : synopsis. 7. Valais. 8. Tessin. 8.1 Canton du Tessin : Synopsis I (programme général). 8.2 Canton du Tessin : Synopsis II (activités en cours). Annexe 1 : 21 buts de santé pour la Suisse (Santé Publique Suisse). Annexe 2 : 7 thèses sur la nouvelle réglementation de la prévention et de la promotion de la santé en Suisse (Office fédéral de la santé publique).

Prevalence of frailty indicators and association with socioeconomic status in middle-aged and older adults in a swiss region with universal health insurance coverage : a population-based cross-sectional study

Frailty prevalence in older adults has been reported but is largely unknown in middle-aged adults. We determined the prevalence of frailty indicators among middle-aged and older adults from a general Swiss population characterized by universal health insurance coverage and assessed the determinants of frailty with a special focus on socioeconomic status. Participants aged 50 and more from the population-based 2006-2010 Bus Santé study were included (N = 2,930). Four frailty indicators (weakness, shrinking, exhaustion, and low activity) were measured according to standard definitions. Multivariate logistic regressions were used to determine associations. Overall, 63.5%, 28.7%, and 7.8% participants presented no frailty indicators, one frailty indicator, and two or more frailty indicators, respectively. Among middle-aged participants (50-65 years), 75.1%, 22.2%, and 2.7% presented 0, 1, and 2 or more frailty indicators. The number of frailty indicators was positively associated with age, hypertension, and current smoking and negatively associated with male gender, body mass index, waist-to-hip ratio, and serum total cholesterol level. Lower income level but not education was associated with higher number of frailty indicators. Frailty indicators are frequently encountered in both older and middle-aged adults from the Swiss general population. Despite universal health insurance coverage, household income is independently associated with frailty.

Newer antiepileptic drugs in the treatment of status epilepticus: impact on prognosis

Background: Newer antiepileptic drugs (AED) are increasingly prescribed, and seem to have a comparable efficacy as the classical AED, but are better tolerated. Very scarce data exist regarding their prognostic impact in patients with status epilepticus (SE). We therefore analyzed the evolution of prescription of newer AED between 2006-2010 in our prospective SE database, and assessed their impact on SE prognosis.¦Methods: We found 327 SE episodes occurring in 271 adults. The use of older versus newer AED (levetiracetam, pregabalin, topiramate, lacosamide) and its relationship to outcome (return to clinical baseline conditions, new handicap, or death) were analyzed. Logistic regression models were applied to adjust for known SE outcome predictors.¦Results: We observed an increasing prescription of newer AED over time (30% of patients received them at the study beginning, vs. 42% towards the end). In univariate analyses, patients treated with newer AED had worse outcome than those treated with classical AED only (19% vs 9% for mortality; 33% vs 64% for return to baseline, p<0.001). After adjustment for etiology and SE severity, use of newer AED was independently related to a reduced likelihood of return to baseline (p<0.001), but not to increased mortality.¦Conclusion: This retrospective study shows an increase of the use of newer AED for SE treatment, but does not suggest an improved prognosis following their prescription. Also in view of their higher price, well-designed, prospective assessments analyzing their impact on efficacy and tolerability should be conducted before a widespread use in SE.

Temporal variability of antibiotics fluxes in wastewater and contribution from hospitals.

Significant quantities of antibiotics are used in all parts of the globe to treat diseases with bacterial origins. After ingestion, antibiotics are excreted by the patient and transmitted in due course to the aquatic environment. This study examined temporal fluctuations (monthly time scale) in antibiotic sources (ambulatory sales and data from a hospital dispensary) for Lausanne, Switzerland. Source variability (i.e., antibiotic consumption, monthly data for 2006-2010) were examined in detail for nine antibiotics--azithromycin, ciprofloxacin, clarithromycin, clindamycin, metronidazole, norfloxacin, ofloxacin, sulfamethoxazole and trimethoprim, from which two main conclusions were reached. First, some substances--azithromycin, clarithromycin, ciprofloxacin--displayed high seasonality in their consumption, with the winter peak being up to three times higher than the summer minimum. This seasonality in consumption resulted in seasonality in Predicted Environmental Concentrations (PECs). In addition, the seasonality in PECs was also influenced by that in the base wastewater flow. Second, the contribution of hospitals to the total load of antibiotics reaching the Lausanne Wastewater Treatment Plant (WTP) fluctuated markedly on a monthly time scale, but with no seasonal pattern detected. That is, there was no connection between fluctuations in ambulatory and hospital consumption for the substances investigated.

Newer antiepileptic drugs in the treatment of status epilepticus: Impact on prognosis.

Newer antiepileptic drugs (AEDs) are increasingly prescribed and seem to have a comparable efficacy as the classical AEDs; however, their impact on status epilepticus (SE) prognosis has received little attention. In our prospective SE database (2006-2010), we assessed the use of older versus newer AEDs (levetiracetam, pregabalin, topiramate, lacosamide) over time and its relationship to outcome (return to clinical baseline conditions, new handicap, or death). Newer AEDs were used more often toward the end of the study period (42% of episodes versus 30%). After adjustment for SE etiology, SE severity score, and number of compounds needed to terminate SE, newer AEDs were independently related to a reduced likelihood of return to baseline (p<0.001) but not to increased mortality. These findings seem in line with recent findings on refractory epilepsy. Also, in view of the higher price of the newer AEDs, well-designed, prospective assessments analyzing the impact of newer AEDs on efficacy and tolerability in patients with SE appear mandatory.